Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Mar 31, 2016
Filed with the SEC on May 11, 2016 and accepted by EDGAR at May 11, 2016, 08:40 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2016-01-01 to 2016-03-31 | $4.1m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-01-01 to 2016-03-31 | −$15.6m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2016-01-01 to 2016-03-31 | −$15.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-01-01 to 2016-03-31 | −$0.68 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-01-01 to 2016-03-31 | −$0.68 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-01-01 to 2016-03-31 | 23,130,153 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2016-01-01 to 2016-03-31 | −$11.5m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Cash and equivalents | At period end2016-03-31 | $134.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-03-31 | $135.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-03-31 | $136.3m | us-gaap:Assets |
| Current liabilities | At period end2016-03-31 | $11.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-03-31 | $14.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-03-31 | $121.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-16-005855. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.